Life forward - Boehringer Ingelheim unveils its evolved company brand
Life forward - Boehringer Ingelheim unveils its evolved company brand
Search
Our People, Our Culture
Our People, Our Culture
Top-line Phase II Data for treatment of MASH
Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).
Outside the lab…inside the family
We are a manufacturing and a research company too. Outside of the lab, we have engineers, legal teams, logistics managers, QA/QC teams and more.
See our Locations
We offer career development opportunities in over 170 locations across the world. Explore some of our featured locations.
Ethics and Compliance
Ethics and Compliance
Biosimilars
: A biosimilar is a version of a biologic medication that is made by a different company than the one that invented it, with no clinically meaningful differences in terms of safety, potency and purity.
Our Mission
Our Story
Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches
Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches
Sustainable Development - Our Commitment
Our Commitment
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
Full data announced in phase III EMPA-KIDNEY trial
The EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD)
Cleaning up the coast for a greener future
Employees from our Fremont site connect with nature and clean up the environment.
Results from Phase II MASH trial announced at EASL 2024
Boehringer Ingelheim announced results from Phase II trial in metabolic dysfunction-associated steatohepatitis (MASH) at EASL 2024
AbeXXa Biologics – Re-Imagining Cancer Immunotherapy for the Many
AbeXXa Biologics – Re-Imagining Cancer Immunotherapy for the Many
Corporate Social Responsibility | Boehringer Ingelheim US
Boehringer Ingelheim has a strong and longstanding commitment to improving the health of people and animals, both around the world and in local communities.
More Green | Sustainable Development | Boehringer Ingelheim US
Our MORE GREEN pillar encompasses initiatives that consider many different aspects: adopting measures to avoid water and air pollution, & much more.
Corporate Profile
Corporate Profile
My journey to advance diversity, equity and inclusion in the workplace
Hear from one of our employees, Tanisha Archer-Parkes, on the importance of diversity in the workplace and continuing to move toward a more inclusive and accepting society.
Accessibility Statement
Boehringer Ingelheim endeavors to make https://www.boehringer-ingelheim.com accessible to any and all users.
Making Toys for Shelter Animals | Boehringer Ingelheim US
Find out how nearly 400 Boehringer Ingelheim employees came together to make toys out of donated t-shirts for animals living in shelters across the USA.
Management Rotation
Click here to read testimonies from our employees who enrolled in our management rotation program.
Work life wellness
We provide you with a range of benefits and services, including counselling, exercise classes, social events to help you stay mentally and physically fit.
Pharmacy Rotations
Click here to read testimonies from our employees who enrolled in our pharmacy rotations academic program.
Fur-ever homes: How pet shelters and fosters have met the challenge of the pandemic
Pet shelters impacted by the COVID-19 pandemic have benefitted from the Stay Home and Foster program, which connects shelter pets with foster homes.